Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

Abstract Background In the Phase III INPULSIS® trials, treatment of patients with idiopathic pulmonary fibrosis (IPF) with nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo, consistent with slowing disease progression. However, nintedanib was n...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Michael Kreuter, Wim A. Wuyts, Marlies Wijsenbeek, Sabrina Bajwah, Toby M. Maher, Susanne Stowasser, Natalia Male, Wibke Stansen, Nils Schoof, Leticia Orsatti, Jeffrey Swigris
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	BMC 2020-01-01
Цуврал:	Respiratory Research
Нөхцлүүд:	SGRQ UCSD-SOBQ CASA-Q EQ-5D VAS
Онлайн хандалт:	https://doi.org/10.1186/s12931-020-1298-1
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!